Banked Primary Progenitor Cells for Allogeneic Intervertebral Disc (IVD) Therapy: Preclinical Qualification and Functional Optimization within a Cell Spheroid Formulation Process
Jeannerat A., Peneveyre C., Jaccoud S., Philippe V., Scaletta C., Hirt-Burri N.
Laboratory Study on Back Pain, Disc Degeneration, published in Pharmaceutics (2024) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Laboratory Study
- Journal
- Pharmaceutics (2024)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 39458605
- PMCID
- PMC11510186
- DOI
- 10.3390/pharmaceutics16101274
Abstract (original English)
Background/Objectives: Biological products are emerging as therapeutic management options for intervertebral disc (IVD) degenerative affections and lower back pain. Autologous and allogeneic cell therapy protocols have been clinically implemented for IVD repair. Therein, several manufacturing process design considerations were shown to significantly influence clinical outcomes. The primary objective of this study was to preclinically qualify (chondrogenic potential, safety, resistance to hypoxic and inflammatory stimuli) cryopreserved primary progenitor cells (clinical grade FE002-Disc cells) as a potential cell source in IVD repair/regeneration. The secondary objective of this study was to assess the cell source's delivery potential as cell spheroids (optimization of culture conditions, potential storage solutions). Methods/Results: Safety (soft agar transformation, β-galactosidase, telomerase activity) and functionality-related assays (hypoxic and inflammatory challenge) confirmed that the investigated cellular active substance was highly sustainable in defined cell banking workflows, despite possessing a finite in vitro lifespan. Functionality-related assays confirmed that the retained manufacturing process yielded strong collagen II and glycosaminoglycan (GAG) synthesis in the spheroids in 3-week chondrogenic induction. Then, the impacts of various process parameters (induc
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.
Related research
- Level ASystematic ReviewEurope PMC
Stem cell therapy for degenerative disc disease: A systematic review of preclinical evidence, clinical translation, and future directions
Systematic Review on Back Pain, Disc Degeneration, published in N Am Spine Soc J (2026) — summary generated from the PubMed abstract.
- 2026
N Am Spine Soc J - Level ASystematic ReviewEurope PMC
Role of Platelet-Rich Plasma (PRP) in the Management of Stage III and IV Degenerative Disc Disease
Systematic Review on Back Pain, Disc Degeneration, Chronic Inflammation, published in Cureus (2025) — summary generated from the PubMed abstract.
- 2025
Cureus1 citations - Level ASystematic ReviewPubMed
Comprehensive Evidence-Based Guidelines for Regenerative Therapies in the Management of Chronic Low Back Pain: 2025 Update from the American Society Of Interventional Pain Physicians (ASIPP).
Systematic Review on Back Pain, Scar, published in Pain Physician (2025) — summary generated from the PubMed abstract.
- 2025
Pain Physician - Level AMeta-analysisPubMed
Mesenchymal Stromal Cells for the Treatment of Discogenic Low Back Pain: A Systematic Review of Clinical Studies.
Meta-analysis with a reported sample of 736 on Back Pain, Disc Degeneration, published in Neurospine (2025) — summary generated from the PubMed abstract.
- 2025
- n = 736
Neurospine1 citations - Level ASystematic ReviewEurope PMC
Sirtuins in intervertebral disc degeneration: current understanding
Systematic Review on Back Pain, Disc Degeneration, Chronic Inflammation, published in Mol Med (2024) — summary generated from the PubMed abstract.
- 2024
Mol Med11 citations - Level ASystematic ReviewEurope PMC
A comprehensive review of cell transplantation and platelet-rich plasma therapy for the treatment of disc degeneration-related back and neck pain: A systematic evidence-based analysis
Systematic Review on Back Pain, Disc Degeneration, published in JOR Spine (2024) — summary generated from the PubMed abstract.
- 2024
JOR Spine22 citations